Nurix Advances Phase 3 CLL Trial, Posts $6.3M Q1 Revenue and $540.7M Cash
Nurix ended Q1 with $540.7 million in cash and reported $6.3 million revenue, down from $18.5 million as Sanofi collaboration research term concluded. The company advanced its bexobrutideg program into Phase 2 DAYBreak CLL-201 and plans mid-2026 initiation of Phase 3 confirmatory and IND filings for inflammation.
1. Clinical Pipeline Progress
Nurix continues to enroll patients in the DAYBreak CLL-201 Phase 2 trial in relapsed/refractory CLL to support an Accelerated Approval application and plans to initiate the global randomized confirmatory Phase 3 DAYBreak CLL-306 trial by mid-2026 comparing bexobrutideg to pirtobrutinib. A healthy volunteer SAD/MAD study of a new tablet formulation is underway to support a 2026 IND submission for inflammatory and autoimmune indications.
2. Strategic Collaborations
Partnerships with Sanofi and Gilead advance IND-enabling STAT6 and first-in-human IRAK4 degrader programs respectively, with Nurix retaining rights to opt in for a 50/50 U.S. profit share after proof of concept or Phase 1 milestones; additional collaboration milestones are expected with Pfizer across various pipeline assets.
3. Q1 Financial Results
In the quarter ended February 28, 2026, Nurix reported $6.3 million revenue versus $18.5 million year-ago, driven by completion of a Sanofi research term. R&D and G&A expenses rose to $84.1 million and $14.6 million respectively as clinical and manufacturing activities accelerated, while cash reserves stood at $540.7 million.